AVR vs BSX
AVR: A pre-revenue structural heart company pioneering a biomimetic, single-piece aortic valve designed to replicate healthy valve hemodynamics and durability in TAVR-eligible patients with aortic stenosis. BSX: Boston Scientific is a leading medical technology company delivering minimally invasive interventional solutions to improve patient health across diverse clinical specialties.
Side-by-side fundamentals
| Metric | AVR | BSX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.35 | $42.97 | |
| Market cap as of 2026-07-23 | $815M | $63.7B | |
| P/E as of 2026-07-23 | n/a | 17.88 | |
| PEG as of 2026-07-23 | n/a | 0.24 | |
| Net margin as of 2026-07-23 | -5148.8% | +17.3% | BSX higher |
| Gross margin as of 2026-07-23 | +74.3% | +69.1% | AVR higher |
| Operating margin as of 2026-07-23 | -5192.9% | +18.4% | BSX higher |
| ROE as of 2026-07-23 | -64.7% | +14.9% | BSX higher |
| ROA as of 2026-07-23 | -101.2% | +8.3% | BSX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.43 | AVR lower |
| Revenue growth (YoY) as of 2026-07-23 | -0.5% | +17.4% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +16.5% | |
| Dividend yield as of 2026-07-23 | n/a | +0.0% | |
| Beta as of 2026-07-23 | 2.04 | 0.58 | |
| 1-year return as of 2026-07-22 close | +182.5% | -58.3% | AVR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.